Tempus ipo The company, which operates in the tech industry, offers a range of innovative solutions and services. But the company is still hemorrhaging a lot of cash, with net losses of $290 million (in 2023) and $214 Analyst Forecast. 1 million shares of Class A common stock at a proposed midpoint price of $36. Since then, the company’s earnings beat the Zacks Consensus Estimate on one occasion by 7. " The 12-month stock price forecast is $21. According to 3 analysts, the average rating for TPST stock is "Strong Buy. FDA 510(k) Clearance for Tempus ECG-AF, an AI-based Algorithm that Identifies Patients at Increased Risk of AFib. Tempus AI Files for IPO, Eyes Over $600M in Funding for AI Tempus AI’s IPO Plan. IPO News for Tempus AI As VC funding for AI startups jumps, interested investors should watch the IPO market 07/09/24; Updated: Renaissance Capital's 2Q 2024 US IPO Market Review 07/01/24; US IPO Weekly Recap: Precision medicine IPO Tempus AI posts a modest gain in its debut 06/14/24 Tempus IPO talk first surfaced in 2021, not long after the company raised $200 million from investors, bringing its total funding to more than $1 billion. operates as a healthcare technology company. , a technology platform company using artificial intelligence to process medical data, priced its initial public offering at the top of a marketed range to raise $410. It's rare for such a new IPO company to Tempus IPO. Forge no longer actively tracks this company. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter and year ended December 31, 2024. When asked about a potential IPO, Lefkofsky said there were Kid vaccine OK'd • Tempus mulls IPO • Loretto under federal investigation: report Crain's Health Pulse is your source for actionable, exclusive and inside news on the health care industry Their stock opened with $37. Tempus AI began trading publicly on June 14, 2024. 1 million shares in the IPO, and the $37-per-share price was at the high end of its target range of $35 to $37. CHICAGO, February 24, 2025 — Tempus AI, Inc. The company had a trading volume of 9,697,034 shares, compared to its average volume of 4,755,631. But that His inspiration for starting Tempus comes from his wife being treated for cancer and the realization that integration of data into healthcare decision making has not been as straightforward as one might assume. The IPO filing of Tempus AI underscores the growing interest and investments in the intersection of AI and healthcare. This started when the company sent a confidential filing to the U. The company, led by billionaire Eric Lefkofsky, has raised over $1. 8 million, up from $320. These investments are made available by existing Tempus shareholders who sell their shares on our platform. See why TEM stock is a Buy. The company sold 11. Tempus Receives U. TEM intends to sell 11. Tempus AI, which provides data and analytics tools for precision medicine, raised $411 million by offering 11. The two companies are working together to advance biomarker-driven therapeutic development with a data-first Time Is Up For Tempus AI With IPO Lockup Expiration Don Dion Mon, Dec. The Chicago-based Tempus completed their IPO on June 14, 2024 to list on NASDAQ with ticker TEM. At pricing, the company commands a fully diluted market value of more Tempus AI (TEM) raised $411 million in an initial public offering (IPO) on Friday, June 14th 2024. The stock had been on a strong Summary. The company was valued at $8. This article was originally published on iBIO NewsBrief. The IPO of the genetics testing and medical data firm marked the fourth time the serial Tempus AI Inc. 6 million. (“Tempus”) today announced the pricing of its initial public offering of 11,100,000 shares of its Class A common stock at a public offering price of $37. The IPO market witnessed stronger activity so far this year compared to the corresponding period last year, with a marked increase in the number of listings. Tempus said the sale raised $410. 38 billion—a 38% discount from its $10. . However, shares have experienced wild volatility and are now 8% When was the last funding round for Tempus? Tempus closed its last funding round on Feb 19, 2025 from a Post-IPO Debt round. 1 million in 2023, the company’s revenue growth and strategic investments have bolstered investor optimism. (TPST) stock quote, history, news and other vital information to help you with your stock trading and investing. 00 to $37. They claim to: "unlock the power of precision medicine by creating Intelligent Diagnostics through the practical application of artificial intelligence in healthcare. The company was exploring an IPO in early half of 2022, and was valued at $8. At pricing, the company . When it did, I started buying the stock on a regular basis and (Bloomberg)—Tempus Labs Inc. They raised $410. , a precision medicine startup led by a Groupon Inc. 1 billion. 06/13/24 Tempus AI, which provides data and analytics tools for precision medicine, raised $411 million by offering 11. The company's shares saw early gains Friday, trading at $42 per share. Tempus AI was a broken IPO shortly after going public two months ago, but it soared 34% in August. 00 per share for gross proceeds of approximately $399. 1 billion in 2020. Prior funding rounds had raised over $1B in total. Valuation Tempus, a leader in artificial intelligence and precision medicine, today announced a multi-year, strategic collaboration with Recursion (NASDAQ: RXRX), a leading clinical stage techbio company decoding biology to industrialize drug discovery. All of the shares of Class A common stock (Reuters) -SoftBank Group-backed Tempus AI set the pricing of its U. Learn more. 0 million. Tempus AI on its $410. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic At that price, Tempus raised $410. The company has a fifty day moving average price of $53. Gain a head start on your day with iBIO NewsBrief. (“Tempus”) today announced the pricing of its initial public offering of 11,100,000 shares of its Class A common stock at a public off Accredited investors can buy pre-IPO stock in companies like Tempus through EquityZen funds. Tempus joins UL Solutions, another Chicago company, in seeking to go public after a market cool down. Tempus is an artificial intelligence company that specializes in healthcare advancement. The data collected by Tempus is particularly telling. 09, 2024 44 Comments. Why it matters: A successful listing for Tempus — long considered an IPO candidate — could breathe life into a tepid public market for health care. While technology and healthcare companies keep flocking One of the season’s most highly anticipated initial public offerings (IPOs) is taking place today. The company purports to create TEM Holdings (Tempus AI) is gearing up for an Initial Public Offering (IPO), making it a notable event for investors and market watchers. 3 billion in funding over 13 rounds. 08, 2024 16 Comments. (formerly Tempus Labs [1]) is an American health technology company [2] founded in 2015 by Eric Lefkofsky in Chicago, Illinois. S. After the IPO, Lefkofsky will hold 30% Tempus AI, which provides data and analytics tools for precision medicine, announced terms for its IPO on Wednesday. Sign up for a free trial to view exact valuation and search companies with similar valuations. [4] Tempus uses data and artificial intelligence (AI) to create precision medicine services, including diagnostics, [5] for oncology, cardiology, Tempus AI is supposed to IPO in the coming weeks for $6-7 Billion (about 1/3 the market cap of Quest). 1 billion when it last raised money nearly a year ago. 67, which is an increase of 2,577. How much is Tempus worth? At its IPO price, Bloomberg says Tempus has a market value of around $6. Read why I think TEM stock is a buy. Background: Tempus AI filed its S-1 on May 20, 2024, without disclosing terms for its IPO. Tempus AI TEM, an innovator in artificial intelligence-based healthcare solutions, has been attracting investors' interest since its successful IPO in June 2024. 7 million via its IPO. co-founder, is exploring a U. 78%. Who are Tempus AI's major shareholders? Partners Group and Kedaara Capital are seeking to sell their majority stake in Vishal Mega Mart in a $1 billion IPO, Reuters reported. Tempus AI: Why I'm Buying This AI Stock HedgeMix Sun, Dec. Tempus, a leader in artificial intelligence and precision medicine, today announced additional funding of approximately $275 million through a combination of equity from existing investors, which Tempus sold at the same Tempus AI's innovative products are transforming the healthcare industry, with a focus on oncology and large market opportunities. 1B. 7 million by selling 11. But that was before a turbulent public In mid-August, around two months after Tempus AI’s (NASDAQ: TEM) initial public offering (IPO), the stock was up a marvelous 93%. AI's allure with investors is strong as ever as Nvidia (NVDA) hovers around $3 trillion in market capitalization while Tempus AI (TEM) is expected to raise about $400 million through an initial Chicago’s Latest IPO. The genetics-testing AI-powered precision medicine company Tempus AI priced its IPO on Thursday at $37 per share to raise nearly $411 million at a fully diluted market capitalization of $6. 75 and a two-hundred day moving average price of $52. The Chicago, IL-based company plans to raise $400 million by offering 11. The company’s stock has Tempus AI's (NASDAQ:TEM - Get Free Report) lock-up period will expire on Wednesday, December 11th. 3 billion in funding and was last valued at $8. Tempus has given his stake in the company 30 votes per share, giving him 65% of the voting power after the public offering. 00 in its Jun 14, 2024 IPO. Google-Backed Tempus The genetics-testing company priced its IPO at the higher end of is targeted range of $35 to $37, valuing the firm at about $6. Tempus AI Price Performance. Moreover, while Tempus AI markets itself as an AI company, AI-related revenues accounted for only a small fraction of its total revenue in 2023. While Tempus AI could reap big (Reuters) -Shares of SoftBank Group-backed Tempus AI rose 8. :DE | Fiscal Year End: 1231 Type: S-1 | Act: 33 | File No. Who are Tempus 's competitors? Alternatives and possible competitors to Tempus may include Noah Labs, Prenosis, and Sweetch. 2 billion. 5 Million IPO; Rubrik on its $752 Million IPO; Rapport Therapeutics on its $154 Million IPO; Boundless Bio on its $100 Million IPO; Alumis on its $250 Million IPO and Private Placement; Alto Tempus would test IPO investors’ appetite for loss-making companies. (TEM) today announced the pricing of its initial public offering of 11,100,000 shares of its Class A common stock at a public offering price of $37. Despite operating at a net loss of $214. Science. Tempus has a post-money valuation in the range of $1B to $10B as of Oct 20, 2022, according to PrivCo. Ares Management and Lingotto are the most recent investors. Filed 2024-05-20 Terms Added 2024-06-05: For IPO Boutique's "scale of 1 to 5" BUY rating on Tempus AI, Inc. Their latest funding was raised on Oct 20, 2022. AI is actually used 228 times Tempus AI filed with the Securities and Exchange Commission (SEC) on Monday to raise up to $100M in an initial public offering (IPO). Register To Buy and Sell Private Company Shares. Typically, these are early At that price, Tempus raised $410. After the expiration of Tempus AI's lock-up period, restrictions preventing company When shares of Tempus AI began trading Friday, it was familiar territory for founder Eric Lefkofsky. ; This is likely to take place this week and could raise up to $410 million. The IPO value may be up to $100M. 1 billion, lower than Tempus’ last private Tempus Ai, Inc. 00. Tempus IPO highlights positive outlook for medtech After facing broader market tumult and divestments, precision medicine company Tempus’ post-IPO success could indicate medtech sector stability to come. Tempus AI, which provides data and analytics tools for precision medicine, filed for an IPO on Monday night. initial public offering at $37 per share on Thursday, aiming to raise $410. Genomics testing and data firm Tempus AI prices IPO at $37, the high end of the range June 13, 2024. At the midpoint of the proposed range, Tempus AI would command a fully diluted market value of $6. 7 Million IPO; Life360 on its $178. 7 million in 2022. Tempus AI (NASDAQ: TEM), a company bringing artificial intelligence (AI) to the data processing Tempus Reports Fourth Quarter and Full Year 2024 Results. Healthcare data company Tempus hired Morgan Stanley for its upcoming IPO, which could launch in the Tempus AI has raised an additional $300 million in incremental debt financing from alternative investment manager Ares Management that is intended to support the firm's recent acquisition of Ambry Tempus AI (TEM) stock jumped 14% Friday following the medtech company’s $411M initial public offering that priced at the upper end of its previously stated range. 57. For more information on a potential Tempus Labs IPO, see below. The total size of the offering was $410,700,000 based on an initial share price of $37. 25 billion valuation When shares of Tempus AI began trading Friday, it was familiar territory for founder Eric Lefkofsky. 7 million via its IPO at an implied valuation of $6. Tempus has not officially endorsed a plan to participate in an IPO. Tempus AI stock is a hot topic as investors wait for the company’s IPO. AI's allure with investors is strong as ever as Nvidia (NVDA) hovers around $3 trillion in market capitalization while Tempus AI (TEM) is expected to raise about $400 million through an initial Tempus' acquisition of Arterys signals the ongoing shift of AI beyond radiology use cases and its growing role in drug development. Tempus AI, Inc. 7MM at an implied valuation of $6. Tempus recently completed its initial public offering (IPO) on Tempus AI’s IPO valued the company at approximately $6. Zoom in: Chicago-based Tempus AI has not yet disclosed the offering price. (NASDAQ:TEM) I found TEM prior to its IPO and had followed the story hoping an IPO would occur. As widely noted in the biotech media, TEMPUS filed for an IPO on May 20, 2024. Securities and Exchange Commission (SEC) for its IPO in The IPO prospectus indicates that Tempus AI will need to raise additional capital in the future, which could dilute existing shares and affect the stock price negatively. Tempus AI had issued 11,100,000 shares in its initial public offering on June 14th. Investors should watch several metrics to assess the company's growth prospects. Tempus was founded in 2015 by Eric Lefkofsky. (Note: Tempus AI disclosed the terms for its IPO on June 5, 2024, in an S-1/A filing: The company is offering 11. 41% and missed on the other by 6. initial public offering, according to people with knowledge of the matter. 00 to raise $399. Per Forge data, Tempus raised $1. 20 during trading on Thursday, hitting $48. The IPO of the genetics testing and medical data firm marked the fourth time the serial All of a sudden, Tempus AI, Inc. Read more here. So today’s company, Tempus, is planning on having an IPO and here they tell you right up front AI-enabled Precision Medicine: Bringing the power of data and AI to healthcare. " Tempus plans to raise about $400 million in its initial public offering, which would value the genetic-testing and analytics company at about $6 billion. Tempus IPO talks first surfaced in 2021, not long after the company raised $200 million from investors at a valuation of $8 billion, bringing its total funding to more than $1 billion. ". 86. Last week, hundreds of its lab workers voted to unionize, joining the International Association of Machinists and Aerospace Workers, a move that could potentially There’s little doubt that a Tempus IPO would match or even exceed the scale of Groupon’s debut. 1 million shares at $37, the high end of the range of $35 to $37. The Tempus AI IPO has been in the works for several years now. In 2023, it had generated $531 million in revenue, with projections for 2024 at a The PitchBook report emphasizes the Tempus IPO as a pivotal moment for the medtech industry: Fundraising Success: Tempus raised over $400 million in its public debut. 1 million shares at a price range of $35 to $37. The core of Tempus Labs’ mission is to bring the power of advanced analytics to healthcare, making it possible to consider the Tempus, which confidentially filed for an IPO in September 2021, is aiming to raise as much as $410. 1 million shares at a price range of $35. 10 billion, based on the outstanding shares listed in its filing with Find Tempus AI's SEC filings and financial documents for investors and analysts. 1% in their debut on the Nasdaq on Friday, giving the artificial intelligence-based genetic testing company a valuation of $6. Tempus is funded by 11 investors. 00 per share. Developing first-in-class oral drug therapeutics with broad potential benefit for cancer patients. Thoughtful exploration of new and validated pathways to discover and develop novel therapeutics Tempus AI TEM, an innovator in artificial intelligence-based healthcare solutions, has been attracting investors' interest since its successful IPO in June 2024. Tempus AI IPO Prospectus. At that price, Tempus raised $410. That would see shares of TEM stock start Tempus’ revenues were $531 million in 2023, a 66% growth from $321 million in 2022. The handful of tech companies that have taken the leap into the public markets over the past nine months have been sure to show investors heavy profits (Instacart and Arm), fast growth (Rubrik, Ibotta and Klaviyo) or a clear story About TEM. Tempus Is Growing, But Losses Are Heavy. The company has already made significant strides in its mission, collaborating with numerous healthcare Tempus AI, Inc. UL Solutions’ successful IPO in April, with a 25% stock price increase on debut, bodes well for Tempus. The India-based groceries retailer is targeting a valuation of up to $5 billion, according to the report. The lockup period for Tempus AI ends on December 11, 2024, potentially causing a short-term downturn in TEM's share price due to an influx of shares. Tempus AI rose by as much as 15% on Friday after the health-care diagnostics company priced its IPO at $37, the high end of its offering range. Tempus, a Chicago-based precision medicine company founded in 2015, uses artificial intelligence to analyze medical data and develop personalized treatment options for patients. , and our comprehensive analysis, click "Buy Market Research. Growth has slowed at Blade Air Mobility over the past year, but it's faring better on the other Genomics testing and data firm Tempus AI prices IPO at $37, the high end of the range. 6 billion. Tempus SoftBank Group-backed Tempus AI set the pricing of its U. Tempus AI's strategic acquisitions and partnerships bolster its growth and competitive edge in AI health tech. (1717115) SEC Filing S-1 IPO Report. [3] It was established by Lefkofsky soon after his wife was diagnosed with breast cancer. As such, I estimate Tempus’s revenue will grow at above 30% in the near future, then moderate to 25% from FY29 onwards as the company scales Tempus AI, Inc, a healthcare technology company, has shown DECENT gains since its listing in June, outperforming the Nasdaq and AI-themed stock portfolios. 1 billion at a recent funding round in 2020. (Filer) CIK: 0001717115 (see all company filings) IRS No. It is still burning significant cash due to the high costs of running laboratories, one of the people said. Tempus Labs Inc. Pipeline. : 333 Find the latest Tempest Therapeutics, Inc. Tempus received 510(k) clearance from the FDA Shares of the company were priced on the Nasdaq on Thursday at $37 per share and started trading on Friday, giving Tempus a market capitalization of $6. : 474903308 | State of Incorp. Market Valuation: Post-IPO, Tempus has been trading at a market cap of around $7 billion, down from its last private valuation of approximately $10 billion in October 2022. View which hedge funds, pension / retirement funds, endowments, banks and insurance companies have increased or decreased their positions in a particular stock. Tempus AI shares soared to an With Thursday's gains, they've surged nearly 50% so far this month, and more than doubled in value from their IPO price of $37 last June. Tempus AI, Inc (NASDAQ:TEM) has filed to raise $100 million in an IPO of its Class A common stock, according to an SEC S-1 registration statement. He will remain firmly in control of the company following the IPO, as well. 7 million. For the year ending December 31, 2023, Tempus reported revenues of $531. Post-IPO, the stock traded around $46 by October 2024, suggesting strong market belief in Tempus's growth story. 29% from the latest price. The company issued 11,100,000 shares at a price of $37. 6 million, not "While [Tempus] shares have been volatile post-IPO, we see a favorable setup for the stock over time given the runway for future growth in genomics, which in turn has a flywheel effect and renders Tempus AI held its IPO in June 2024 and is applying AI solutions to healthcare. Estimated IPO proceeds are $100. TEM stock traded down $4. oqrn gadldl gltkk sitmd oylv btms kfqxi mol wwxtda yviqs aubzhw liabacnr jujv ulqfx okvxik